The Future of CAR-T Cell Therapy Special Interest: Group Meeting Report

This report summarizes discussion across 12 working group sessions covering the scientific, manufacturing, clinical, regulatory, and commercial development of CAR-T cell therapy, addressing three modalities – autologous, allogeneic, and in vivo CAR-T. Participants did not identify any single modality as likely to dominate: the choice of modality and manufacturing model was seen to depend on indication and region, with the three formats expected to coexist. Cost of goods and safety were identified as the principal barriers to patient access, underlying most reimbursement and clinical delivery questions. Standardization was judged achievable for safety-relevant attributes and chain of custody/identity, but limited for product-specific attributes such as potency. This report sets out where the field stands, what the most experienced people in the sector believe needs to change, and where coordinated action across organizations is both necessary and achievable, giving readers a clear picture of the critical decisions, the available options, and the open questions that remain.

Read the full report below